Nuvation Bio Sets Date for Second Quarter 2026 Financial Review
Nuvation Bio will detail its second quarter 2026 financial performance and provide a broader update on its oncology pipeline during a conference call scheduled for August 6, 2026, at 8:00 a.m. ET. The session aims to offer stakeholders a clear view of the company's current development milestones.
Investors and interested observers can access the live discussion via the company’s investor relations portal. For those joining by phone, the conference line is available at 1-833-461-5787 using the access code 762246460. Following the live event, Nuvation Bio plans to maintain an archived recording on its website for a period of 90 days.
Founded in 2018 by industry veteran David Hung, the company continues to focus on complex cancer therapies, including its ROS1 inhibitor taletrectinib and the brain-penetrant IDH1 inhibitor safusidenib. The firm maintains a global presence with offices across New York, San Francisco, Boston, and Shanghai as it pushes forward its current drug-drug conjugate research programs.
Comments (0)
No comments yet. Be the first!